US FDA approve Factive for cystitis indication

Published: 2010-01-12 06:58:00

Updated: 2010-01-12 06:58:00

LG Life Sciences says that the United States Food and Drug Administration (FDA) approved its additional efficacy supplement for Factive (gemifloxacin mesylate) to treat cystitis, in adidition to mild-to-moderate community- acquired pneumonia (CAP) due to multi-drug resistant Streptococcus pneumon...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK